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A Mouse Mutation in the 12R-Lipoxygenase, Alox12b,
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Nonbullous congenital ichthyosiform erythroderma (NCIE) is a nonsyndromic form of autosomal recessive
congenital ichthyosis characterized by hyperkeratosis and a disruption in the epidermal permeability barrier.
Identification of mutations in two lipoxygenases (LOXs), ALOX12B (12R-LOX) and ALOXE3 (eLOX3), and further
functional studies implicate ALOX12B and ALOXE3 in the etiology of NCIE. Here, we report a mutation in
Alox12b in the recessive ethylnitrosurea-induced mouse mutant, mummy (Alox12bmmy-Bei). mummy mutants
have red, scaly skin and die perinatally. Histologically, mummy mutants display defects in the epidermis. We
mapped mummy to a 1.9 Mb interval on Chr. 11 containing Alox12b (12R-LOX), Aloxe3 (eLOX3) and Alox15b
(8-LOX). Sequencing of all three genes identified a nonsense mutation in the catalytic domain of Alox12b. We
demonstrate that mummy mutants have a disrupted epidermal permeability barrier and that the nonsense
mutation in mummy abolishes the enzyme activity of 12R-LOX. The mummy mutant provides a mouse model for
LOX-mediated NCIE and is the first described mouse mutant affecting epidermal barrier formation identified by
forward genetics.
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INTRODUCTION
The epidermal permeability barrier is a specialized epidermal
structure that protects the skin from dehydration and the entry
of chemical or infectious agents and is essential for terrestrial
life. Barrier function is provided by the stratum corneum, the
outer layer of the epidermis composed of terminally
differentiated keratin-filled cells with crosslinked cornified
envelopes (CEs) sealed by lipid bilayers. Incomplete barrier
function in humans is observed in premature infants,
inflammatory skin diseases such as psoriasis, and in
congenital ichthyoses (reviewed in Richard, 2004; Segre,
2006).
Nonsyndromic autosomal recessive congenital ichthyosis
(ARCI) is a genetically and clinically heterogeneous class of
skin diseases marked by scaly skin and impaired epidermal
barrier function. The most common clinical cases of ARCI are
of two types: lamellar ichthyosis (LI) and nonbullous
congenital ichthyosiform erythroderma (NCIE, CIE, or NBCIE)
(reviewed in Akiyama et al., 2003). The genetic basis of
several ARCI loci have been identified, and mutations in
some genes can result in multiple forms of ARCI (reviewed in
Akiyama et al., 2003; Richard, 2004; Akiyama, 2006). Many
ARCI disease genes encode proteins involved in the synthesis
of the CE or epidermal lipid metabolism, such as TGM1, a
transglutaminase that crosslinks the CE; ABCA12, an ATP-
binding cassette transporter involved in lipid trafficking, and
ALOX12B and ALOXE3, two lipoxygenases (LOXs) involved
in fatty acid metabolism.
In the mouse, several genes required for epidermal barrier
function have been identified. These include CE and
intercellular junction structural proteins, proteins involved
in CE protein crosslinking and lipid synthesis, and transcrip-
tion factors (reviewed in Segre, 2003, 2006). Two such genes
are known human congenital ichthyoses disease genes: Tgm1
(autosomal recessive LI and NCIE) and loricrin (autosomal
dominant NCIE) (reviewed in Richard, 2004). Here, we
describe the first mouse mutation in the 12R-LOX, Alox12b,
which is mutated in some human NCIE-affected individuals.
RESULTS
The recessive mummy mutant was identified in an ethyl-
nitrosurea mutagenesis screen for recessive neonatal develop-
mental defects (Herron et al., 2002). Affected mice are born
with red, shiny skin that rapidly desiccates and appears scaly
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(Figure 1a and b). The mutation causes lethality within
24 hours of birth. Histological analysis of newborn epidermis
demonstrates a thickened, compressed stratum corneum in
the affected mice in contrast to the normal basket-weave
corneum layers in unaffected littermates (Figure 1c and d).
The initial map position of the mummy mutation was
determined by genotyping 10 affected intercross progeny and
two parentals with a fixed whole genome single nucleotide
polymorphism (SNP) panel of 394 SNPs (Moran et al., 2006).
Retention of homozygous alleles for the mutagenized strain
(A/J) and positive logarithm of odds (LOD) association at a
single locus demonstrates linkage (LOD 2.81) to a 21 Mb
interval on chromosome (Chr) 11 (rs4228770 (58.1 Mb) –
rs13481117 (79.0 Mb) (Figure 2a)). The genetic interval was
further refined to 1.9 Mb (D11Mit115 (67.4 Mb) –D11Mit298
(69.3 Mb)) by genotyping recombinant affected mice and an
additional 15 affected progeny with simple-sequence length
polymorphism markers (data not shown). The refined 1.9 Mb
genetic interval contains 41 RefSeq genes.
Three genes in the 1.9 Mb genetic interval, Alox12b,
Aloxe3, and Alox15b, were evaluated for candidates for the
mummy mutation based on several criteria. Firstly, these Alox
genes comprise a family of epithelial-specific LOXs (hepoxy-
lins) expressed in the mouse epidermis (Sun et al., 1998;
Heidt et al., 2000). Secondly, Alox15b (Alox8; 8-LOX)
expression is upregulated in a mouse model of severe
dermatitis (Schneider et al., 2004). Thirdly, mutations in
ALOX12B (12R-LOX) and ALOXE3 (eLOX3) have been
identified in individuals with ARCI, specifically the ARCI
subtype NCIE, an ichthyosis characterized by hyperkeratosis
and a disruption of the epidermal permeability barrier (Jobard
et al., 2002; Eckl et al., 2005). Sequencing of all exons and
intron–exon boundaries from all three genes was performed
on genomic DNA from mummy-affected mutant mice.
We identified a G to A single base pair change in exon 14
of the Alox12b gene (Figure 2b). The Alox12b gene encodes
one transcript with 15 exons and a 701 amino-acid protein.
The mutation introduces a nonsense codon into the
C-terminal LOX catalytic domain (W633X), which results in
truncation of the protein by 68 amino acids. Mutated
transcript is present in mummy homozygote skin, indicating
the absence of nonsense-mediated mRNA decay (data not
shown).
LOXs are lipid-peroxidizing enzymes that oxygenate
polyunsaturated fatty acids to hydroperoxide derivatives
(Samuelsson et al., 1987). Mouse Alox12b protein (12R-
LOX) oxygenates arachidonate methyl ester rather than
arachidonic acid to 12R-hydroperoxyeicosatetraenoic acid
(HETE) (Krieg et al., 1999). To assess the affect of the mutation
on the enzymatic activity of 12R-LOX, we overexpressed
histidine (His)-tagged mutant W633X and wild-type Alox12b
proteins in COS7 cells and assayed for 12R-LOX activity by
incubating cell extracts with [14C]-labeled arachidonic acid
methyl ester substrate. Analysis using reversed-phase high-
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Figure 1. Gross phenotype and histology of newborn mummy mutants.
(a–b) mummy mutants are distinguishable from unaffected littermates at birth
by their red skin that rapidly desiccates and appears scaly. (c–d) Newborn
mummy dorsal skin shows a thickened stratum corneum by hematoxylin and
eosin staining of sections (n¼ 9 affected mice; n¼ 10 unaffected mice,
evaluated at E17.5, E18.5, and newborn). Bar¼150 mm.
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Figure 2. Genetic mapping and identification of the mummy mutation.
(a) The mummy mutation was mapped to a 21 Mb interval on Chr 11 between
SNPs rs4228770 (58.1 Mb) and rs13481117 (79.0 Mb) by performing a whole
genome scan of 394 SNPs on two parental (A/JC57BL/6J) F1 and 10 affected
F2 progeny. Alleles for the mutated A/J strain (M) are red; C57BL/6J
background strain (B), blue; heterozygotes, yellow; and no calls, white. P for
parental; U for unaffected and A for affected mice. Genotypes from two
nonrecombinant simple-sequence length polymorphism markers, D11Mit29
(69.6 Mb) and D11Mit194 (73.2 Mb), are also shown. (b) Chromatograms of
Alox12b genomic sequence in wild-type A/J (top) and mummy-affected
(middle, bottom) mice showing a G to A mutation, which introduces a
premature stop codon in mummy mutants.
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performance liquid chromatography (HPLC) revealed that
wild-type Alox12b converted the substrate to 12R-HETE and
12R-HETE methyl ester, whereas mutant Alox12b-W633X
produced no detectable products (Figure 3). Expression levels
of wild-type and mutant Alox12b proteins, as detected by
Western blotting with an antibody against the His tag, were
equivalent (data not shown). Thus, the mummy mutation
W633X completely eliminates Alox12b enzymatic activity.
Identification of a loss-of-function mutation in mouse
Alox12b, association of mutations in human ALOX12B in
NCIE, and the neonatal mummy phenotype all suggest that
epidermal permeability barrier function may be compro-
mised in mummy mice. Formation of the permeability barrier
is a highly patterned process that begins at E16 in the mouse
and is completed by birth (Hardman et al., 1998). Disruption
of the skin barrier is lethal in mice, as demonstrated by the
study of several perinatal lethal gene-targeted mutations
affecting the skin barrier (reviewed in Segre, 2003; Leyvraz
et al., 2005; Herrmann et al., 2005). To test whether mummy
mutants have a defective skin barrier, a dye permeability
assay was performed on untreated E17.5 and E18.5 fetuses.
X-gal substrate does not penetrate skin with a functional
barrier and accessibility of X-gal to the skin produces a
colored precipitate through endogenous b-galactosidase
activity (Hardman et al., 1998). mummy mutants do not
show evidence of barrier acquisition as demonstrated by blue
staining across the entire body at E17.5 and E18.5 (Figure 4a).
An additional test of skin barrier function is to monitor
mice for dehydration. E17.5 and E18.5 mice were dissected
and revived, and weights were measured every hour for 6 h.
mummy mutants lost between 21 and 27% of their body
weight within 6 hours of birth indicating rapid dehydration,
the likely cause of perinatal lethality (Figure 4b).
DISCUSSION
Here we describe the first mouse mutation in the 12R-LOX,
Alox12b, which was identified in an ethylnitrosurea muta-
genesis screen for recessive perinatal developmental defects.
In mummy (Alox12bmmy-Bei) mice, a nonsense mutation in
Alox12b leads to premature truncation of the protein and loss
of LOX catalytic activity. Alox12b deficiency in mice leads to
a lack of epidermal permeability barrier function and
perinatal lethality. In humans, mutations in ALOX12B
underlie the genetic basis for some cases of NCIE, one of
the main clinical forms of ARCI. Like the mouse nonsense
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Figure 3. Reversed-phase HPLC analysis of catalytic activities of wild-type
and mutant Alox12b. The His-tagged enzymes expressed in COS7 cells were
incubated with [14C]arachidonate methyl ester as substrate and the products
analyzed by reversed-phase HPLC using a Waters Symmetry C18 column
(25 0.46 cm) with a solvent system of methanol/water/acetic acid
(85:15:0.01, by volume) run at a flow rate of 1 ml/minute on an Agilent 2100
series HPLC system equipped with an on-line Flo-One Beta radioactive
detector. Arachidonate methyl ester is used as the test substrate because
mouse 12R-LOX does not metabolize free arachidonic acid (Krieg et al.,
1999). Top trace: profile of unlabeled standards added to the sample before
injection and detected with UV recording at 235 nm. Middle trace:
14C-labeled products formed by wild-type Alox12b – note that the [14C]12-
HETE methyl ester product formed from the [14C]arachidonate methyl ester is
mainly hydrolyzed to the free acid by esterase activity in the COS cell extract
(cf. ref (Krieg et al., 1999)). Lower trace: 14C elution profile from mutant
Alox12b shows no detectable products.
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Figure 4. Analysis of epidermal permeability barrier function in mummy
mice. (a) Widespread permeability of X-gal substrate in affected mice at E17.5
(n¼5/; n¼ 13þ /; n¼ 7/) and E18.5 (n¼ 2/; n¼3 þ /;
n¼ 4þ /þ ) compared with littermate controls. (b) The weight of intercross
progeny was measured every hour for the first 6 hours after birth. Dramatic
weight loss of mummy homozygotes at E17.5 and E18.5 (n¼5/), 21–27%
weight loss compared with no more than 3% for control littermates
(n¼16þ /; n¼ 7þ /þ ), shows a lack of barrier function.
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mutation, all human point mutations tested result in abolish-
ment or significant impairment of 12R-LOX activity (Eckl
et al., 2005; Yu et al., 2005).
The mummy mutant provides a mouse model for human
NCIE, as mummy skin shares some of the features of NCIE-
affected skin. NCIE-affected individuals display erythroder-
mic, scaly skin, an increase in stratum corneum thickness
(hyperkeratosis), inflammation and impaired epidermal bar-
rier function, with a range in phenotype severity (reviewed in
Akiyama et al., 2003). mummy mutants are born with shiny,
red skin that rapidly desiccates because of a defective
epidermal barrier. Histologically, the stratum corneum of
late gestational and neonatal skin is thickened. Although
NCIE is not typically lethal, mummy mice die within 24 hours
of birth, presumably because of rapid dehydration. Thus, we
are not able to observe the effects of Alox12b deficiency in
the adult mouse. Lethality in mice and not humans has also
been observed in transglutaminase-mediated barrier defects
and ARCI, and may be owing to the lack of medical care for
newborn mice or the larger surface area-to-volume ratio of
mice compared with humans (Matsuki et al., 1998; Kuramoto
et al., 2002; Segre 2006).
Alox12b is a member of a family of epithelial-specific
LOXs expressed in neonatal and adult mouse epidermis (Sun
et al., 1998; Heidt et al., 2000). Alox12b mRNA is first
detected in the skin and other epithelial tissues at E15.5 and is
highly expressed in newborn mouse epidermis (Sun et al.,
1998). Alox12b’s expression in late granular and squamous
keratinocytes led to the proposal that Alox12b plays a role in
skin barrier formation and terminal differentiation (Heidt
et al., 2000). The skin barrier begins to form at E16 when a
precursor of the stratum corneum is first detected (Hardman
et al., 1998). We observed a defect in epidermal permeability
barrier (EPB) formation in mummy mice at E17.5. Given the
expression of Alox12b and both the barrier and stratum
corneum defects in mummy mice, we speculate that Alox12b
activity is required for terminal differentiation of keratino-
cytes and formation of a functional stratum corneum. To
elucidate potentially a mechanism for the epidermal defects,
examination of the morphology and integrity of CEs, lipid
synthesis and processing, and ultrastructural cellular archi-
tecture will need to be performed.
The identification of several human ARCI disease genes,
ALOX12B, ALOXE3, ichthyin, and FLJ39501, has led to the
elucidation of an arachidonic acid metabolism LOX-depen-
dent pathway in ARCI pathogenesis (Jobard et al., 2002; Yu
et al., 2003; Lefevre et al., 2004; Lefevre et al., 2006). It is still
unclear whether the LOX-dependent pathway plays a
structural or signaling role in epidermal differentation. The
mouse mutant mummy provides a model that will facilitate
further exploration of the role of LOXs in epidermal barrier
formation and terminal differentiation of the skin.
MATERIALS AND METHODS
Histology
Newborn heads were fixed in Bouin’s, embedded in paraffin,
sectioned and stained with hematoxylin and eosin.
Genetic mapping
mummy was identified in an ethylnitrosurea mutagenesis screen for
autosomal recessive developmental phenotypes (Herron et al.,
2002). The mutation was generated on the A/J strain and maintained
by serial backcross to FVB/NJ. The mutation was outcrossed to
C57BL/6J for mapping and phenotypic analysis. Ten affected
F2-affected progeny and two F1 male parents were genotyped with
a whole genome SNP panel containing 394 SNPs and simple-
sequence length polymorphisms (Moran et al., 2006). Recombinant
affected mice and an additional 15 affected mice were genotyped
with simple-sequence length polymorphism markers to narrow the
genetic interval to 1.9 Mb (D11Mit115 (67.4 Mb) – D11Mit298
(69.3 Mb); Genome Build 36).
DNA sequencing
High-throughput sequencing of exons and exon/intron boundaries of
the Alox12b, Aloxe3, and Alox15b genes was performed as
described previously (Moran et al., 2006). Genomic DNA from the
wild-type A/J strain and two mummy-affected mice were used as
sequencing templates. Alox12b Vega Gene ID:OTTMUSG000000-
005964 (www.ensembl.org/Mus_musculus).
Skin permeability assay
E17.5-E18.5 untreated fetuses were stained with X-gal solution at
low pH to assay endogenous epidermal b-galactosidase activity as
described by Hardman et al. (1998).
Wild-type and mutant Alox12b activity assay
cDNA amplification and cloning. Total RNA was extracted from
wild-type and mutant E18.5 skin with a Qiagen RNeasy Midi Kit
(Qiagen, Valencia, CA). First strand cDNA was synthesized using
Superscript III First Strand cDNA Synthesis Kit (oligo-dT primer;
Invitrogen, Carlsbad, CA) and subsequently used as a template for
polymerase chain reaction (PCR) amplification of wild-type Alox12b
cDNA with Platinum Taq DNA Polymerase High Fidelity (Invitrogen)
and cDNA-specific primers (forward primer 50-GTGGTTCCCGCTG
ACTGC-30; reverse primer 50-TTACAGTGATTTTATTGGA-30). PCR
product was cloned into pCR2.1TOPO and the cDNA sequence was
verified by full-length sequencing.
Wild-type and mutant cDNAs were cloned into the Gateway
system for mammalian expression (Invitrogen). Briefly, the wild-type
Alox12b cDNA pCR2.1TOPO clone was used as a template for PCR
amplification of wild-type and mutant cDNA with Pfx50 DNA
Polymerase (Invitrogen). PCR were performed with a common
forward and distinct reverse primers; the mutant cDNA primer
contained the point mutation (forward 50-CACCATGGCCACCTA
TAAAGTC-30; wild-type reverse primer 30-CAGAAGGGTGGACTA
GATGGA-30; mutant reverse primer 30-GCTCCCGACAGAGAGTT
CAG-30). Products were cloned into the pENTR/SD/D-TOPO vector
using the pENTR Directional TOPO Cloning Kit (Invitrogen)
according to manufacturer’s protocol. After isolation of plasmid
DNA with the Purelink HQ Mini Plasmid Kit (Invitrogen), wild-type
and mutant Alox12b cDNAs were cloned into the Gateway
destination vector pDEST26 (N-terminal fusion vector with in-frame
6His-tag) by LR recombination using Gateway LR Clonase
enzyme mix according to manufacturer’s protocol.
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Transfection and expression of wild-type and mutant proteins
Subconfluent COS7 cells were transiently transfected using a 1:4
ratio of plasmid to FuGENE 6 Reagent (Roche Applied Science,
Indianapolis, IN) according to the manufacturer’s instructions. After
48 hours, cells were rinsed and harvested in phosphate-buffered
saline, pelleted, and then sonicated in 200 ul buffer (50 mM Tris (pH
7.5) and 150 mM NaCl) on ice using a Virsonic 100 (Virtis) at setting
6 for 10 seconds.
12R-LOX activity assay
Reversed phase-HPLC analyses of wild-type and mutant cell lysates
were performed essentially as described (Chen et al., 2006). Briefly,
100ml of sonicated cell lysates were incubated with freshly purified
[1-14C]arachidonic acid methyl ester (500,000 d.p.m., added in 1 ul
of ethanol, 50 mM final concentration) at 371C for 30 minutes. Lipids
were extracted using a Bligh and Dyer protocol, evaporated to
dryness under nitrogen and stored in methanol at 201C. Extracts
were analyzed by reversed-phase HPLC using a Waters Symmetry
C18 column (25 0.46 cm) with a solvent system of methanol/water/
acetic acid (80:20:0.01, by volume) run at a flow rate of 1 ml/minute
on an Agilent 2100 series HPLC system with Diode Array Detector
and on-line Flo-One Beta radioactive detector. Before injection, a
mixture of unlabeled HETE standards and 12-HETE methyl ester was
added to each sample to help establish the precise retention times for
comparison with 14C-labeled products.
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